| Literature DB >> 16753240 |
Luisa L Villa1, Kevin A Ault, Anna R Giuliano, Ronaldo L R Costa, Carlos A Petta, Rosires P Andrade, Darron R Brown, Alex Ferenczy, Diane M Harper, Laura A Koutsky, Robert J Kurman, Matti Lehtinen, Christian Malm, Sven-Eric Olsson, Brigitte M Ronnett, Finn Egil Skjeldestad, Margareta Steinwall, Mark H Stoler, Cosette M Wheeler, Frank J Taddeo, Jimmy Yu, Lisa Lupinacci, Radha Railkar, Rocio Marchese, Mark T Esser, Janine Bryan, Kathrin U Jansen, Heather L Sings, Gretchen M Tamms, Alfred J Saah, Eliav Barr.
Abstract
Human papillomavirus (HPV) infection causes cervical cancer and genital warts. Young women (1106) were randomized to receive one of three formulations of a quadrivalent HPV (Types 6/11/16/18) L1 virus-like particle (VLP) vaccine or one of two placebo formulations. The goal was to assess vaccine safety and immunogenicity in baseline HPV 6/11/16 or 18-naïve and previously infected subjects. All three formulations were highly immunogenic. At Month 2 (postdose 1), among women with vaccine-type antibodies at baseline, vaccine-induced anti-HPV responses were approximately 12- to 26-fold higher than those observed in baseline-naïve women, suggesting an anamnestic response. Following an initial, similar sized decline, anti-HPV responses plateaued and remained stable through end-of-study (3.0 years). No vaccine-related serious adverse experiences were reported.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16753240 DOI： 10.1016/j.vaccine.2006.04.068
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641